NCT06709131View on ClinicalTrials.gov

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

August 17, 2025

Study Completion Date

August 17, 2026

Conditions
Relapsed/Refractory Acute Myeloid Leukemia(AML)
Interventions
DRUG

CAR-T cells（ chimeric antigen receptor T cells）

CAR-T cells（ chimeric antigen receptor T cells）

Trial Locations (1)

310003

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
lead

He Huang

OTHER